Neuro-Pain Medical Center is seeking patients for a clinical trial evaluating an investigational medication for people diagnosed with Parkinson’s disease who are experiencing conditions such as seeing and hearing things that may not be there. The study will help to provide valuable safety information. Patients are contributing to valuable clinical research.
The SEP361-203 Study
SEP-361-203 study, sponsored by Sunovion, is evaluating the safety and tolerability of SEP363856 in subjects with Parkinson’s Disease Psychosis This study is accepting male and female participants 55 years of age and older who have been diagnosed with Parkinson’s Disease. This study will be conducted in 24 study centers in the United States. The study will last approximately 21 weeks.
Who is Neuro-Pain Medical Center?
Led by Dr. Perminder Bhatia, MD, a certified Neurologist, and Principal Investigator and Director, since 2003, he has completed more than 100 clinical trials and published a research paper titled “Lesion Location Related to Type of Affective Disorder After Stroke.” Neuro-Pain Medical Center handles Phase I-IV studies in the Fresno area. Fresno, California, in California’s Central Valley, has nearly 1 million in the Metro area representing one of the most diverse population-based in America.
We include a YouTube video on Dr. Bhatia from CentralValley Talk.
Dr. Perminder Bhatia, MD, a Certified Neurologist, and Principal Investigator and Director